rediff.com

NewsApp (Free)

Read news as it happens
Download NewsApp

Available on  

Rediff News  All News 
Rediff.com  » Sports » French laboratory suspended from anti-doping activities

French laboratory suspended from anti-doping activities

November 04, 2017 10:45 IST

IMAGE: The head office for the World Anti-Doping Agency in Montreal, Canada. Photograph: Christinne Muschi/Reuters

France's main anti-doping laboratory, already under a provisional ban, has been suspended from carrying out anti-doping activities for up to six months because of analytical issues, the World Anti-Doping Agency (WADA) said on Friday.

The new suspension, which took effect on October 31, prohibits the Chatenay-Malabry laboratory from all analyses of urine and blood samples, WADA said.

During the suspension, samples that have not yet been analysed by the Paris laboratory, samples currently undergoing a confirmation procedure and any samples for which an adverse analytical finding has been reported must be securely transported to another WADA-accredited laboratory.

The laboratory was provisionally suspended on September 24 due to issues self-reported to WADA by the laboratory.

Since then disciplinary proceedings were carried out by an independent disciplinary committee, which made a recommendation on the status of the laboratory's accreditation to the WADA Executive Committee chair.

The laboratory, where disgraced American cyclist Lance Armstrong's samples were tested, may appeal this decision to the Court of Arbitration for Sport (CAS) within 21 days of receipt of notice.

If the laboratory addresses all non-conformities identified by the Laboratory Expert Group or WADA, it may apply for reinstatement prior to the expiry of the six month suspension period.

Should the laboratory not address the non-conformities by the end of the six-month suspension period, WADA may extend the suspension of the laboratory’s accreditation for an additional six months, WADA said.

Source:
© Copyright 2018 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.